Main Menu Jump to Page

View Complaint
Retainer Agreement
info@rosenlegal.com

Edge Therapeutics shareholders have an opportunity to recover their investment losses.

Click "Join this Class Action" above.

Attorneys

Edge Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Edge Therapeutics, Inc. (NASDAQ: EDGE) from December 29, 2017 through March 27, 2018, both dates inclusive. The lawsuit seeks to recover investor losses.

If you purchased shares of Edge Therapeutics between December 29, 2017 and March 27, 2018 and would like to join the action, please click "Join This Class Action" above.

Press Release

EQUITY ALERT: Rosen Law Announces Filing of Securities Class Action Lawsuit Against Edge Therapeutics, Inc. – EDGE

New York, N.Y., April 27, 2018. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Edge Therapeutics, Inc. (NASDAQ: EDGE) from December 29, 2017 through March 27, 2018, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Edge Therapeutics investors under the federal securities laws.

To join the Edge Therapeutics class action, go to http://www.rosenlegal.com/cases-1330.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or  zhalper@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Edge Therapeutics’ lead product candidate, EG-1962, would likely fail a futility analysis in connection with the NEWTON 2 study; and (2) as a result, Edge Therapeutics’ financial statements and defendants’ statements about the company’s business, operations, and prospects, were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 22, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1330.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or zhalper@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm was Ranked No. 1 by Institutional Shareholder Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Zachary Halper, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      zhalper@rosenlegal.com
      www.rosenlegal.com